Tag: Humacyte
Humacyte announces commercial launch of Symvess for extremity vascular trauma
Humacyte today announced the commercial launch of Symvess (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury...
US FDA approves Humacyte’s Symvess for vascular trauma
Humacyte recently shared that the US Food and Drug Administration (FDA) has granted a full approval for the Symvess acellular tissue-engineered vessel.
A press release...
Vascular News’ top 10 most popular stories of November 2024
Late-breaking data shared at VIVA 2024 (3–6 November, Las Vegas, USA), the first-in-human implantation of a new bridging stent, and an interview with Ramon Varcoe...
Humacyte clinical results published in JAMA Surgery
Humacyte today announced the publication of clinical results evaluating the efficacy and safety of the acellular tissue engineered vessel (ATEV) in the repair of...
Vascular News’ top 10 most popular stories of July 2024
Several company updates including Series A funding for Endoron Medical, new insights on the role of machine learning in determining endovascular aneurysm repair (EVAR)...
Humacyte pioneers off-the-shelf, universally implantable Acellular Tissue Engineered Vessel (ATEV)
The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
NOTE: This video is...
Humacyte’s ATEV granted US FDA Regenerative Medicine Advanced Therapy designation for...
Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its investigational...
Human Acellular Vessel Biologics License Application granted priority review by US...
Humacyte has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review to Humacyte’s Biologics License Application (BLA) seeking...
Humacyte submits Biologics License Application to US FDA seeking approval of...
Humacyte today announced that it has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking approval of the...
Vascular News’ top 10 most popular stories of September 2023
Discussions on the role of aritifical intelligence in the vascular field and emerging deep venous valve technologies caught readers' attention in September.
1. Humacyte announces...
MVSS 2023: Human Acellular Vessel proves ‘safe, effective bypass conduit’ in...
An investigator-sponsored clinical study conducted at the Mayo Clinic in Rochester, Minnesota, of the investigational Human Acellular Vessel (HAV) in patients with chronic limb-threatening...
Humacyte announces positive top line results from Phase 2/3 trial of...
Humacyte has announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair.
A...
Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel...
Humacyte today announced completion of enrolment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA)...
Humacyte publish six-year outcomes in study of HAV for peripheral arterial...
Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced...
Human-tissue engineered blood vessels remain durable at six years in PAD...
Mid-term results from a phase II study of surgical bypass using the Human Acellular Vessel (HAV; Humacyte) demonstrated an overall secondary patency rate at...
Ukrainian surgeons present clinical update on Human Acellular Vessel in vascular...
Humacyte recently announced the presentation of a clinical update on the Human Acellular Vessel (HAV) for the treatment of vascular trauma. The update was...
Humacyte provides update on patients treated at front-line hospitals in Ukraine...
Humacyte today announced that the first Ukrainian patients have received implants of the Human Acellular Vessel (HAV) for the treatment of vascular trauma injuries....
Humacyte’s Human Acellular Vessel for limb salvage evaluated in multiple complex...
Humacyte today announced results from the first series of compassionate use cases of the company’s investigational Human Acellular Vessel (HAV) for the treatment of...
Humacyte to present long-term follow-up data from Phase 2 vascular access...
Humacyte has announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in haemodialysis...
Humacyte commences phase II vascular trauma trial
Humacyte has announced the initiation of a US phase II vascular trauma clinical trial of Humacyl, its investigational human acellular vessel, for vascular replacement...
Humacyte appoints Doug Blankenship as chief financial officer
Humacyte has announced the appointment of Douglas L Blankenship as chief financial officer, effective Monday, 8 October, 2018.
According to a company release, Blankenship is...
Humacyte appoints Jeffrey Lawson as president and CEO
Humacyte, an innovator in biotechnology and regenerative medicine, has announced that Jeffrey Lawson has been appointed president and chief executive officer. The former chairman...
Fresenius and Humacyte enter strategic global partnership with US$150M equity investment
Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, have announced...
Humacyte’s Humacyl receives US FDA expedited review designation
The US Food and Drug Administration (FDA) has granted Humacyte’s Humacyl investigational human acellular vessel (HAV) Regenerative Medicine Advanced Therapy (RMAT) designation.
This designation means...
Humacyte commences US phase II arterial bypass clinical trial
Humacyte has announced the initiation of a US phase II arterial bypass clinical trial of Humacyl, an investigational human acellular vessel, to test its safety...
